Home
    Registration
    Accommodation
    Webcasting
    Contact
     Home
     Welcome Note
     Our Vision
     Committees
     Industry Advisory Board (IAB)
     Scientific Programme
         Satellite Symposia
     Timetable
     CME
         CME Certificate
     Abstract Submission
         Poster Presentations
         Poster Presentation Guidelines
         Best Abstracts Competition
     Registration
         Accompanying Persons Program
         Invitation Letter
     Accommodation
         Hilton Prague Hotel
         Hilton Prague Old Town Hotel
         Corinthia Hotel Prague
         Clarion Congress Hotel
         Panorama Hotel Prague
     Sponsors
     Sponsorship & Exhibition
         Sponsorship Categories
     General Information
         Before you travel...
     About Prague
         Transportation
         Hints and Tips
     CODHy 2006
     CODHy 2008
     CODHy 2008 Webcasting
     CODHy 2008 Abstract Winners
     CODHy 2010 Webcasting
     CODHy Latin America
     CODHy Asia Pacific
     Partners
     Contact Us
The 3rd World Congress on
Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)

Hilton Hotel, Prague, Czech Republic, May 13-16, 2010
 
  Program table Print
Thursday, May 13, 2010
 Welcome Reception
19:30-21:00

Friday, May 14, 2010

Hall A

Hall B

Hall C

08:30-10:00
Plenary Session 1
Chairpersons:  S. Del Prato, I. Raz
OUTCOME STUDIES IN THE TREATMENT OF TYPE 2 DIABETES (T2D)
Diabetes and Cancer
S. Del Prato    
Implications of the new regulatory guidelines: cardiovascular outcome studies as an integral part of the development process of novel anti diabetic drugs
B. Hirshberg
What can we learn from the new ACCORD sub analysis? 
H. Ginsberg
Act Now
R.A. DeFronzo
 
10:00-10:30
Coffee break
10:30-12:30
Session 2
Chairperson:  J.J. Holst
GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS: A CLINICAL COMPARISON
Glycaemic control impact on body weight potential to reduce CV risk
GLP-1: G. Sesti
DPP-4: D. Dicker
Beta-cell protection
Animal studies: M. Donath
Human perspective: A.J. Garber
PANEL DISCUSSION
D. Dicker, M. Donath, A.J. Garber G. Sesti
Session 3
Chairperson:  G. Mancia, Y. Yodfat
OPTIMAL BLOOD PRESSURE CONTROL
The blood pressure legacy
Pro: L. Ruilope
               Con: G. Parati                
Blood pressure: The lower, the better
Pro: G. Mancia 
Con: A. Zanchetti  
PANEL DISCUSSION  
G. Mancia, G. Parati, L. Ruilope, A. Zanchetti
Session 4
Chairperson:  E. Ravussin 
OBESITY: CAUSE AND DIFFERENT APPROACHES
Should obesity be treated at any age?
R. Bonadonna
Physical exercise. How and how much?
P. De Feo
Effective diet for weight loss
I. Shay
Caloric restriction V's bariatric surgery
E. Ravussin
PANEL DISCUSSION
R. Bonadonna, P. De Feo, E. Ravussin, I. Shai
12:30-13:30
Lunch break
13:30-14:15
Plenary Session 5
NORMALIZING A1C – EFFICACY AND SAFETY OF NEW NOVEL DRUGS
 R.A. DeFronzo
14:15-16:00
Session 6
Chairpersons:  A. Ametov, J. Meigs
THERAPY IN THE EARLY STAGE
Pharmacologic prevention of T2DM
Pro: R.A. DeFronzo
Con: J. Tuomilehto
Metformin failed: What is next?
Incretins: S. Del Prato
Others: I. Raz
PANEL DISCUSSION
R.A. DeFronzo, S. Del Prato, , I. Raz, J. Tuomilehto
Session 7
Chairperson:  E. Grossman
HYPERTENSION TREATMENT
Are the benefits of RAS blockage beyond BP lowering in CV prevention?
Y. Yodfat
 Diuretics treatment of hypertension
Pro: E. Grossman
Con: P. Verdecchia
PANEL DISCUSSION
E. Grossman, P. Verdecchia, Y. Yodfat
Session 8
Chairpersons:   R. Niecestro, M. Petkova
GLUCOSE VARIABILITY
Postprandial glucose and glucose variability: Should we care?
Pro: A. Ceriello
Con: E. Standl
Continuous glucose monitoring (closing the loop)
Expectations: M. Philip
Humbles: J.H. DeVries
PANEL DISCUSSION
A. Ceriello, J.H. DeVries, M. Philip, E. Standl
16:00-16:30
Coffee break
16:30-18:30
Session 9
Chairpersons:  R.C. Bonadonna,
S. Chernia,
T2D IN CHILDHOOD
Epidemiology and pathophysiology
S. Caprio
Metabolic syndrome in pediatrics
R. Weiss
The accelerator hypothesis and the double diabetes
P. Pozzilli
Treatment of T2D in youth: What's on the Horizon?
S. Arslanian 
 PANEL DISCUSSION
S. Arslanian, S. Caprio, P. Pozzilli, R. Weiss, S. Arslanian 
Session 10 
Chairperson:  L.M. Ruilope
RAS AND COMPLICATIONS
eGFR or albuminuria
as predictor for renal and CV outcome
eGFR: M. Ravid
Albuminuria: D. de Zeeuw 
 RAS blockade for every diabetic
Pro:  L. Ruilope
Con: A. Solini
PANEL DISCUSSION
D. de Zeeuw, M. Ravid,  L. Ruilope, A. Solini
Session 11
Chairperson:  C.D.A. Stehouwer
VESSELS, ENDOTHELIUM AND METABOLIC DISEASES
Inflammation and innate immunity
J.M. Fernández-Real
The role of metalloproteinases: At the interface between metabolic and inflammatory disorders
M. Federici
Vascular disease in diabetes: The role of repatory mechanisms
A. Avogaro
Endothelial factors and diabetic nephropathy
L. Gnudi
PANEL DISCUSSION
A. Avogaro,  M. Federici, J.M. Fernández-Real, L. Gnudi



Saturday, May 15, 2010

Hall A

Hall B

Hall C

08:30-10:00
Session 12 
Chairpersons:  P. Home, H. Toplak
LIPIDS IN THE WRONG PLACE
Islet fat
E. Ravussin
Intramyocellular
R.A. DeFronzo
Visceral fat/ NASH
G. Perseghin
Myocardial/Perivascular/ Epicardical fat
P. Iozzo
Session 13
Chairpersons: G. Jermendy H. Lebovitz
THERAPY IN COMPLEX PATIENTS WITH TYPE 2 DIABETES CURRENT LIMITATIONS & FUTURE TREATMENT OPTIONS 
Renally impaired T2DM
E. Ritz
T2DM with vascular complications. What is the target? Which treatment?
P. Pozzilli 
Multidrug treatment of T2DM, a challenge for compliance
S. Del Prato
PANEL DISCUSSION
S. Del Prato, P. Pozzilli, E. Ritz
Session 14
Chairpersons: A. Keidar
BARIATRIC SURGERY FOR T2DM REVERSAL
The evidence
G. Schernthaner
The mechanism
M. Fried 
The risk
A. Keidar
PANEL DISCUSSION  
M. Fried, A. Keidar, G. Schernthaner
10:00-10:30
Coffee break
10:30-12:30
Session 15
Chairperson: B. Frier J. Skrha
HYPOGLYCEMIA AND CV RISKS
Hypoglycemia and CV risks
B. Frier
ACCORD, ADVANCE and VADT
G. Schernthaner
Hypoglycaemia and it's potential contribution to fatal cardiac arrhythmias in T1D and T2D
S. Heller
PANEL DISCUSSION
B. Frier, S. Heller, G. Schernthaner
Session 16
Chairperson: R. Fagard 
INSULIN THERAPY
Insulin therapy in type 2 diabetes
Not too soon: H. Lebovitz
Not too late: L. Meneghini
HbA1c targets should be individualized for all patients with DM
Pro: P. Home
Con: L. Leiter
PANEL DISCUSSION
H. Lebovitz
PANEL DISCUSSION
P. Home,H. Lebovitz, L. Leiter, L. Meneghini
 
Session 17
Chairperson: H. Rosolova, A. Zambon
PREVENTION OF CVD
Diabetic dyslipidemia
statin Vs. combination therapy
Pro: R. Bitzur
Con: A. Zambon
Risk assessment of universal treatment
J. Meigs
PANEL DISCUSSION
R. Bitzur, J. Meigs, A. Zambon
12:30-13:15
Lunch break
13:30-14:15
 
POSTER GUIDED TOURS
Posters Area
 
Session 18
Oral Presentations
14:00-16:00
Session 19
Chairpersons:  E. Bonora, J. Davidson
SAFETY – OPEN QUESTIONS
Incretins
J. J. Holst 
Sulfonylurea
J. Davidson
PPAR-agonists: Safety issues
P. Home 
PANEL DISCUSSION
J. Davidson, P. Home
 
Session 20
Chairpersons:  L. Meneghini, A. Rubinstein
NOVEL DRUGS FOR DIABETES
Novel mechanisms for the treatment of T2DM
H. Katzeff  
The role of bile acid in T2D treatment
Y. Handelsman
Anticoagulatation for every diabetic? Pro: E. Standl
Con: A. Nicolucci
PANEL DISCUSSION 
Y. Handelsman, H. Katzeff, A. Nicolucci, E. Standl
Session 21
Chairperson:  P.M. Nilsson
SMOKING CESSATION - GET READY FOR SUCCESS!
Evolutionary perspectives on addiction leading to smoking, obesity and drug abuse
P.M. Nilsson
Nicotine dependence: 
Why, how and when?
K.O. Fagerström 
Smoking. The global epidemic
R. Fagard
Smoking cessation strategies. The evidence. Non-pharmacological support
and counseling
P. Tønnesen
PANEL DISCUSSION
R. Fagard, K.O. Fagerström, P.M. Nilsson, P. Tønnesen
16:00-16:30
Coffee break
16:30-18:30
Session 22
Chairpersons:  L.A. Leiter, M. Shestakova
HYPERGLYCEMIA AND CVD
Is hyperglycemia a CV risk factor?
Pro: M. Hanefeld
Con: A. Natali
Heart in diabetes
A macrovascular disease:
D. Tschöpe
A microvascular disease:
M. Laakso
PANEL DISCUSSION
M. Hanefeld, M. Laakso, A. Natali, D. Tschöpe
Session 23
Chairpersons:  N.M. Lalic, R.A. DeFronzo
PHARMACOLOGICAL APPROACHES TO THE MANAGEMENT OF OBESITY
Benefits of calorie intake control
N. Stern
Comparative efficiency and safety
V. Hainer
Sibutramine on CV outcome
A. Scheen
PANEL DISCUSSION
V. Hainer, A. Scheen, N. Stern
Session 24
Chairperson:  J.P. Després
THE CARDIOMETABOLIC BENEFITS OF MODERATE WEIGHT LOSS
Obesity management: Beyond weight loss
R. Ross
Reducing visceral adiposity/ ectopic fat: A better therapeutic target than weight loss?
J.P. Després 
Variation in body weight associated with hypoglycaemic medication: more than a side effect in type 2 diabetes
M. Theodorakis 
Novel hypoglycemic agents inducing weight loss
J.J. Holst
PANEL DISCUSSION
J.P. Després, J.J. Holst, R. Ross, M. Theodorakis 
  



Sunday, May 16, 2010

Hall A

Hall B

08:30-10:00
Session 25
Chairperson: A. Natali 
HYPERTENSION IN DIABETES
Vascular disease endothelial function and clinical implication and endothelium: Target for therapy
A. Natali 
Microvascular dysfunction as a central factor linking obesity to diabetes and hypertension 
C.D.A. Stehouwer
PANEL DISCUSSION
A. Natali, C.D.A. Stehouwer
Session 26
Chairpersons: D. Micic, E. Standl
CARDIOVASCULAR RISK FACTORS
Should CRP be a target of therapy?
L.A. Leiter
A1C Debate
Pro: E. Bonora
Con: J. Tuomilehto
PANEL DISCUSSION
E. Bonora, L.A. Leiter, J. Tuomilehto
10:00-10:30
Coffee break
10:30-12:30
Session 27
BEST ABSTRACTS AWARD
Chairperson:  I. Raz
FUTURE THERAPY OF T2D
GK Activator: F. Matschinsky
SGLT2: E. Boutati
Long Acting GLP1:  A.J. Garber 

Home   
Copyright © 2007 Comtecmed.com. All rights reserved.   The website was last updated on 08/26/2010 Created by    WebStudio.co.il